Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17254433 | COMPOSITIONS AND METHODS FOR PROTEIN LABELING, MODIFICATION, ANALYSIS, AND TARGETED DELIVERY | December 2020 | September 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 17252035 | COMPOSITION FOR DIAGNOSIS OF BONE METASTASIS OF CANCER AND KIT COMPRISING SAME | December 2020 | March 2025 | Abandon | 51 | 3 | 0 | No | No |
| 16972404 | INHIBITORS OF SHP2 | December 2020 | June 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17059995 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING CD300C EXPRESSION INHIBITOR OR ACTIVITY INHIBITOR | November 2020 | November 2024 | Abandon | 48 | 3 | 1 | Yes | No |
| 17099547 | USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT | November 2020 | December 2023 | Allow | 37 | 1 | 1 | No | No |
| 17084751 | ANTI-CD19 THERAPY IN COMBINATION WITH LENALIDOMIDE FOR THE TREATMENT OF LEUKEMIA OR LYMPHOMA | October 2020 | September 2024 | Abandon | 47 | 4 | 0 | No | No |
| 17051018 | FERROCHELATASE INHIBITORS AND METHODS OF USE | October 2020 | July 2024 | Allow | 45 | 2 | 1 | Yes | No |
| 17050832 | HLA-J AND MEDICAL/DIAGNOSTIC USES THEREOF | October 2020 | November 2023 | Abandon | 36 | 1 | 1 | No | No |
| 17050620 | HIGH AFFINITY MONOCLONAL ANTIBODIES (MABS) AGAINST CELL SURFACE EXPRESSED HUMAN CARBONIC ANHYDRASE IX (HCA-IX), AND USES THEREOF | October 2020 | January 2025 | Allow | 51 | 2 | 1 | No | No |
| 17076569 | METHODS OF TREATING HER2-POSITIVE CANCER | October 2020 | December 2023 | Abandon | 37 | 0 | 1 | No | No |
| 17074021 | METHODS OF INACTIVATING GENE EDITING MACHINERIES | October 2020 | April 2025 | Abandon | 54 | 2 | 1 | No | No |
| 17047057 | METHODS OF CANCER TREATMENT USING TUMOR ANTIGEN-SPECIFIC T CELLS | October 2020 | September 2021 | Allow | 11 | 1 | 0 | Yes | No |
| 17046719 | METHOD OF MONITORING RESPONSE TO A TREATMENT | October 2020 | May 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17063617 | COMPOSITIONS AND METHODS FOR MODULATING AND DETECTING TISSUE SPECIFIC TH17 CELL PATHOGENICITY | October 2020 | September 2024 | Allow | 47 | 3 | 1 | Yes | No |
| 17040380 | ANTI-CD137 ANTIBODIES FOR COMBINATION WITH ANTI-PD-L1 ANTIBODIES | September 2020 | March 2024 | Allow | 41 | 3 | 0 | Yes | No |
| 16982476 | PERIOSTIN ANTIBODIES AND METHODS OF USING THE SAME | September 2020 | December 2024 | Allow | 51 | 2 | 1 | Yes | No |
| 16980659 | BISPECIFIC ANTIBODIES TO MOSPD2 AND T CELL- OR NK CELL-SPECIFIC MOLECULES | September 2020 | January 2023 | Abandon | 28 | 1 | 1 | No | No |
| 16979935 | ANTI-CD25 FOR TUMOUR SPECIFIC CELL DEPLETION | September 2020 | February 2023 | Allow | 29 | 2 | 0 | Yes | No |
| 16993950 | NIR-CONJUGATED TUMOR-SPECIFIC ANTIBODIES AND USES THEREOF | August 2020 | May 2023 | Abandon | 33 | 3 | 1 | No | No |
| 16969119 | ANTI-HER2 ANTIBODIES | August 2020 | November 2023 | Allow | 39 | 1 | 1 | Yes | No |
| 16969189 | IgG EPITOPE AND APPLICATIONS THEREOF AS A DRUG TARGET | August 2020 | April 2024 | Allow | 44 | 4 | 1 | Yes | No |
| 16966081 | ANTI-CD47 ANTIBODY AND USE THEREOF | July 2020 | December 2022 | Allow | 29 | 1 | 0 | Yes | No |
| 16940019 | ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3) | July 2020 | October 2023 | Abandon | 38 | 0 | 1 | No | No |
| 16925818 | ANTIGEN BINDING MOLECULES TO TIGIT | July 2020 | July 2023 | Abandon | 37 | 2 | 1 | No | No |
| 16956340 | ENZYME-MEDIATED DEPLETION OF ADENOSINE AND/OR METHYLTHIOADENOSINE | June 2020 | January 2023 | Abandon | 31 | 1 | 1 | Yes | No |
| 16956381 | PREDICTIVE BIOMARKERS FOR TREATMENT OF EYE DISEASES | June 2020 | April 2023 | Abandon | 34 | 0 | 1 | No | No |
| 16772306 | Methods and Combination Therapy to Treat Cancer | June 2020 | December 2022 | Abandon | 30 | 1 | 1 | No | No |
| 16771802 | BIOMARKERS PREDICTIVE OF ANTI-IMMUNE CHECKPOINT RESPONSE | June 2020 | August 2023 | Allow | 38 | 2 | 1 | Yes | No |
| 16890155 | HLA-G Specific Chimeric Antigen Receptor, Nucleic Acid, HLA-G Specific Chimeric Antigen Receptor Expression Plasmid, HLA-G Specific Chimeric Antigen Receptor Expressing Cell, Use Thereof, And Pharmaceutical Composition For Treating Cancer | June 2020 | July 2022 | Allow | 25 | 1 | 0 | No | No |
| 16768838 | COMBINATION THERAPY WITH ANTI-IL-8 ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR TREATING CANCER | June 2020 | December 2022 | Allow | 30 | 2 | 1 | No | No |
| 16768578 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | May 2020 | March 2023 | Abandon | 34 | 1 | 1 | No | No |
| 16886559 | METHODS OF TREATING CANCER | May 2020 | December 2022 | Allow | 30 | 1 | 1 | Yes | No |
| 16879636 | Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors | May 2020 | June 2024 | Abandon | 48 | 2 | 1 | No | No |
| 16764664 | TRANSFORMED HUMAN CELL AND USE THEREOF | May 2020 | January 2023 | Abandon | 32 | 0 | 1 | No | No |
| 16763867 | GP96-BASED CANCER THERAPY | May 2020 | December 2023 | Abandon | 43 | 4 | 0 | No | No |
| 16761848 | CANCER BIOMARKERS AND METHODS OF USE THEREOF | May 2020 | November 2022 | Abandon | 30 | 1 | 1 | No | No |
| 16760776 | IMMUNOSTIMULATORY AGONISTIC ANTIBODIES FOR USE IN TREATING CANCER | April 2020 | October 2022 | Allow | 30 | 2 | 1 | Yes | No |
| 16759371 | TUMOR SPECIFIC ANTIBODIES AND T-CELL RECEPTORS AND METHODS OF IDENTIFYING THE SAME | April 2020 | August 2023 | Allow | 40 | 2 | 1 | No | No |
| 16754852 | HUMAN PD-L1 ANTIBODIES AND METHODS OF USE THEREFOR | April 2020 | July 2022 | Allow | 28 | 1 | 0 | Yes | No |
| 16625936 | Anti-Tumor Immunotherapy Enhancer | April 2020 | April 2023 | Allow | 40 | 2 | 1 | Yes | No |
| 16652079 | ANTI-CD146 ANTIBODIES AND USES THEREOF | March 2020 | April 2022 | Allow | 25 | 1 | 0 | Yes | No |
| 16651959 | CARS AND BISPECIFIC ANTIBODIES FOR TREATMENT OF MANTLE CELL LYMPHOMA | March 2020 | May 2023 | Allow | 38 | 1 | 0 | Yes | No |
| 16648428 | CLAUDIN6 ANTIBODIES AND METHODS OF TREATING CANCER | March 2020 | October 2022 | Abandon | 31 | 0 | 1 | No | No |
| 16645237 | CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS | March 2020 | October 2021 | Abandon | 20 | 0 | 1 | No | No |
| 16784021 | OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP | February 2020 | October 2022 | Allow | 33 | 1 | 1 | Yes | No |
| 16636741 | HSP70 BASED COMBINATION THERAPY | February 2020 | May 2024 | Allow | 52 | 4 | 1 | Yes | Yes |
| 16777345 | HERCEPTIN� ADJUVANT THERAPY | January 2020 | June 2022 | Abandon | 28 | 1 | 0 | No | No |
| 16738535 | RECOMBINANT VACCINIA VIRUS AND METHODS OF USE THEREOF | January 2020 | August 2022 | Allow | 31 | 1 | 1 | Yes | No |
| 16625362 | COMBINATION THERAPIES COMPRISING TARGETED THERAPEUTICS | December 2019 | January 2023 | Abandon | 37 | 1 | 1 | No | No |
| 16620694 | COMBINATION THERAPY WITH ICOS AGONIST AND OX40 AGONIST TO TREAT CANCER | December 2019 | April 2022 | Abandon | 28 | 1 | 0 | No | No |
| 16617487 | CHIMERIC ANTIGEN RECEPTORS TARGETING FLT3 | November 2019 | September 2024 | Allow | 58 | 2 | 1 | Yes | No |
| 16616548 | LYMPHOCYTE ANTIGEN CD5-LIKE (CD5L) MONOMER, HOMODIMER, AND INTERLEUKIN 12B (P40) HETERODIMER AGONISTS AND METHODS OF USE THEREOF | November 2019 | May 2022 | Abandon | 30 | 0 | 1 | No | No |
| 16615112 | ANTI-PD-L1 ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | November 2019 | December 2022 | Allow | 37 | 3 | 0 | Yes | No |
| 16614237 | COMBINATION OF AN ERBB-2/ERBB-3 BISPECIFIC ANTIBODY WITH ENDOCRINE THERAPY FOR BREAST CANCER | November 2019 | November 2024 | Allow | 60 | 4 | 1 | Yes | Yes |
| 16679272 | METHOD FOR TREATING ANTI-HER2 THERAPY-RESISTANT MUC4+ HER2+ CANCER | November 2019 | January 2022 | Abandon | 27 | 2 | 0 | No | No |
| 16610868 | ANTIBODY VARIABLE DOMAINS AND ANTIBODY CONSTRUCTS | November 2019 | September 2022 | Allow | 35 | 2 | 0 | No | No |
| 16610401 | IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD | November 2019 | March 2024 | Allow | 52 | 4 | 1 | No | No |
| 16658047 | COMBINATION IMMUNOTHERAPY FOR TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER | October 2019 | September 2022 | Allow | 35 | 2 | 0 | Yes | No |
| 16657828 | ABITUZUMAB FOR THE TREATMENT OF COLORECTAL CANCER | October 2019 | August 2024 | Allow | 58 | 4 | 1 | Yes | No |
| 16500051 | NK CELL-ACTIVATING FUSION PROTEIN, NK CELL, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | October 2019 | January 2023 | Allow | 39 | 2 | 0 | Yes | No |
| 16499393 | COMPOSITIONS AND METHODS FOR TREATING OVARIAN TUMORS | September 2019 | December 2023 | Allow | 50 | 3 | 1 | Yes | No |
| 16499623 | COMPOSITIONS AND METHODS FOR TARGETING AND KILLING ALPHA-V BETA-3-POSITIVE CANCER STEM CELLS (CSCS) AND TREATING DRUG RESISTANT CANCERS | September 2019 | April 2024 | Abandon | 55 | 5 | 0 | Yes | No |
| 16498505 | ANTIBODY BINDING SPECIFICALLY TO N-TERMINAL REGION OF LYSYL-TRNA SYNTHETASE EXPOSED ON CELL MEMBRANE | September 2019 | February 2023 | Allow | 41 | 2 | 1 | Yes | No |
| 16499095 | BIOMARKERS FOR CANCER THERAPEUTICS | September 2019 | April 2024 | Allow | 55 | 3 | 1 | No | Yes |
| 16498577 | COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER | September 2019 | November 2022 | Allow | 37 | 1 | 1 | Yes | No |
| 16497937 | Compositions and Methods for the Treatment of Cancer | September 2019 | March 2022 | Abandon | 29 | 1 | 0 | No | No |
| 16495874 | PRODUCTION OF RNA BY YEASTS WITH RECOMBINANT PSEUDO-VIRAL PARTICLES | September 2019 | January 2024 | Allow | 52 | 2 | 1 | Yes | No |
| 16576734 | THERAPEUTIC APOPTOTIC CELLS FOR CANCER THERAPY | September 2019 | December 2023 | Allow | 51 | 5 | 1 | Yes | No |
| 16494102 | METHOD FOR THE TREATMENT OF PATIENTS WITH CARCINOMAS | September 2019 | February 2024 | Allow | 53 | 6 | 0 | Yes | No |
| 16489088 | Dosing schedule for a combination of Ceritinib and an anti-PD-1 antibody molecule | August 2019 | November 2021 | Abandon | 27 | 1 | 0 | Yes | No |
| 16488025 | BISPECIFIC BINDING MOLECULES THAT ARE CAPABLE OF BINDING CD137 AND TUMOR ANTIGENS, AND USES THEREOF | August 2019 | May 2022 | Allow | 33 | 3 | 1 | Yes | No |
| 16487272 | FREQUENT EGFR AND NTRK SOMATIC MUTATIONS IN COLORECTAL CANCER (CRC) WITH MICROSATELLITE INSTABILITY (MSI) | August 2019 | May 2024 | Allow | 57 | 2 | 1 | Yes | No |
| 16486741 | CO-USE OF ANTI-BCMA ANTIBODY AND ANTIBODY-COUPLED T CELL RECEPTOR (ACTR) IN CANCER THERAPY AND B CELL DISORDERS | August 2019 | December 2021 | Abandon | 28 | 0 | 1 | No | No |
| 16486688 | ANTI-PD-1 ANTIBODIES FOR TREATMENT OF LUNG CANCER | August 2019 | November 2021 | Allow | 27 | 1 | 0 | Yes | No |
| 16486150 | ANTI-PROGRAMMED DEATH-LIGAND 1 (PD-L1) ANTIBODIES AND THERAPEUTIC USES THEREOF | August 2019 | January 2022 | Allow | 29 | 2 | 0 | Yes | No |
| 16485039 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH ACTIVATION OF THE MAPK PATHWAY | August 2019 | June 2022 | Allow | 34 | 3 | 0 | Yes | No |
| 16535075 | RECOMBINANT BIFUNCTIONAL PROTEIN TARGETING CD47 AND HER2 | August 2019 | May 2022 | Allow | 33 | 2 | 1 | Yes | No |
| 16483943 | METHODS FOR PREDICTING RESPONSIVENESS OF A CANCER TO AN IMMUNOTHERAPEUTIC AGENT AND METHODS OF TREATING CANCER | August 2019 | September 2022 | Allow | 38 | 2 | 1 | Yes | No |
| 16482048 | INHIBITORS OF EPHRIN B1 FOR TUMOR TREATMENT | July 2019 | June 2022 | Allow | 34 | 2 | 1 | Yes | No |
| 16482163 | METHOD OF INDIRECT IMMUNIZATION OF HUMAN OVARIAN CANCER PATIENTS THROUGH SELECTION OF XENOGENEIC IMMUNOGLOBULIN FC PORTIONS | July 2019 | October 2021 | Abandon | 26 | 1 | 0 | No | No |
| 16526694 | BIOMARKERS FOR DISEASE PROGRESSION IN MELANOMA | July 2019 | October 2021 | Abandon | 27 | 1 | 0 | No | No |
| 16479143 | Combinations of Cabozantinib and Atezolizumab to Treat Cancer | July 2019 | August 2021 | Allow | 25 | 1 | 0 | No | No |
| 16516223 | NOVEL ANTIBODIES AND METHODS FOR MAKING AND USING THE SAME | July 2019 | June 2022 | Allow | 35 | 2 | 1 | Yes | No |
| 16475770 | ERBB2 ANTIBODIES AND USES THEREFORE | July 2019 | February 2022 | Allow | 32 | 1 | 1 | Yes | No |
| 16457045 | MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF | June 2019 | February 2022 | Allow | 32 | 1 | 1 | Yes | No |
| 16473576 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | June 2019 | August 2023 | Allow | 50 | 2 | 1 | Yes | No |
| 16447067 | Methods for Treating Cancer with Bispecific Anti-CD3xMUC16 Antibodies and Anti-PD-1 Antibodies | June 2019 | October 2021 | Allow | 28 | 2 | 0 | Yes | No |
| 16434232 | AMHRII-BINDING COMPOUNDS FOR PREVENTING OR TREATING CANCERS | June 2019 | February 2022 | Abandon | 32 | 1 | 1 | No | No |
| 16465601 | COMBINATION THERAPY | May 2019 | February 2022 | Abandon | 33 | 1 | 1 | No | No |
| 16465349 | COMBINATION THERAPY | May 2019 | November 2022 | Abandon | 42 | 2 | 1 | No | No |
| 16417889 | MONOSPECIFIC AND MULTISPECIFC ANTI-TMEFF2 ANTIBODIES AND THEIR USES | May 2019 | May 2023 | Allow | 47 | 4 | 1 | No | No |
| 16417863 | ANTIBODIES SPECIFIC FOR GUCY2C AND USES THEREOF | May 2019 | July 2022 | Allow | 38 | 1 | 1 | Yes | No |
| 16348135 | ANTI-CD46 ANTIBODIES AND METHODS OF USE | May 2019 | April 2022 | Allow | 35 | 2 | 1 | Yes | No |
| 16347397 | IMMUNE MODULATORS FOR REDUCING IMMUNE-RESISTANCE IN MELANOMA AND OTHER PROLIFERATIVE DISEASES | May 2019 | August 2024 | Abandon | 60 | 5 | 1 | Yes | Yes |
| 16347005 | BETA-ALETHINE, IMMUNE MODULATORS, AND USES THEREOF | May 2019 | February 2023 | Allow | 45 | 3 | 1 | Yes | No |
| 16345422 | BIOMARKERS AND TREATMENTS FOR METASTATIC CANCER | April 2019 | June 2022 | Abandon | 37 | 2 | 1 | No | No |
| 16380493 | ANTI-PD-L1 ANTIBODIES AND VARIANTS | April 2019 | October 2021 | Allow | 30 | 1 | 1 | Yes | No |
| 16371589 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER | April 2019 | September 2021 | Allow | 29 | 1 | 1 | Yes | No |
| 16333993 | THE NOVEL MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1) | March 2019 | March 2022 | Allow | 36 | 2 | 1 | Yes | No |
| 16331786 | FUSION PROTEIN AND APPLICATIONS THEREOF | March 2019 | May 2023 | Abandon | 51 | 3 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LU, CHENG.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LU, CHENG works in Art Unit 1642 and has examined 123 patent applications in our dataset. With an allowance rate of 60.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.
Examiner LU, CHENG's allowance rate of 60.2% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by LU, CHENG receive 1.91 office actions before reaching final disposition. This places the examiner in the 43% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by LU, CHENG is 37 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +69.6% benefit to allowance rate for applications examined by LU, CHENG. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 29.6% of applications are subsequently allowed. This success rate is in the 59% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 51.1% of cases where such amendments are filed. This entry rate is in the 78% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 129.4% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 21.6% of allowed cases (in the 95% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.